{"url":"https://whatshealthyandwhy.com/bibhitaki/uric-acid-lipids-and-liver","path":"/bibhitaki/uric-acid-lipids-and-liver","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/bibhitaki/uric-acid-lipids-and-liver.json","markdown":"https://whatshealthyandwhy.com/bibhitaki/uric-acid-lipids-and-liver.md"},"topic":{"slug":"bibhitaki","name":"Bibhitaki","url":"https://whatshealthyandwhy.com/bibhitaki"},"slug":"uric-acid-lipids-and-liver","order":1,"title":"Uric Acid, Lipids, and Liver — Ayurveda's Quiet Triphala Fruit","question":"Does bibhitaki (Terminalia bellirica) lower uric acid?","answer":"Bibhitaki extract may lower uric acid, by roughly 20–34% in two small trials, but less than the drug febuxostat did.","description":"How bibhitaki (Terminalia bellirica), the third fruit in Triphala, lowers uric acid in human trials, supports kidney function, protects the liver, and modulates lipid and glucose metabolism through a gallic-acid-rich tannin profile","confidence":2,"confidenceNote":"Two randomized trials from one research group (110 and 59 people), one without a placebo arm; everything else is lab or animal work.","evidenceSummary":{"rctCount":2,"metaAnalysisCount":1,"totalParticipants":"~170","replicated":false,"newestStudyYear":2020},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["Human trials used standardized extract at 500–2,000 mg a day, split into two doses [1][2].","Capsules or a Triphala blend are easier to take than plain powder, which is strongly astringent."],"cautions":["If you take allopurinol, febuxostat or diabetes medication, monitor lab results and coordinate with a clinician before adding it.","With chronic kidney disease, involve your nephrologist: patients are most sensitive to herb-drug interactions and dose mistakes.","Trials measured blood uric acid, not gout flares, and it lowered uric acid less than febuxostat, so it is not a proven gout treatment [1]."],"simpleText":"Bibhitaki, the dried fruit of Terminalia bellirica, is the third member of the Ayurvedic Triphala formula and the least-discussed of the trio. Modern research has begun to fill in why it earned its place: in two randomized human trials it lowers serum uric acid roughly as well as low-dose febuxostat, the gold-standard gout drug, while also improving kidney filtration markers in chronic kidney disease [1][2]. Its dense gallic acid and tannin chemistry also explains documented effects on liver protection, LDL oxidation, and post-meal glucose handling [3][4][5][6]. Where haritaki is the warming, blood-sugar herb of the three, bibhitaki is the cooling, uric-acid-and-lipid herb.","mediumText":"What Bibhitaki Is\n\nBibhitaki — sometimes spelled bahera, baheda, or vibhitaki — is the fruit of a large deciduous tree native to the Indian subcontinent and Southeast Asia. The dried fruit pulp is one of the three components of Triphala along with haritaki (Terminalia chebula) and amla (Phyllanthus emblica), and it is also used on its own in Ayurvedic preparations targeting respiratory complaints, eye health, and \"ama\" — a traditional concept that maps closely onto modern ideas of metabolic waste buildup. The active chemistry is dominated by hydrolyzable tannins: gallic acid, ellagic acid, chebulagic acid, chebulinic acid, corilagin, and related ellagitannins, with smaller amounts of lignans and triterpenes [7].\n\nHow It Works\n\nThe compound carrying most of bibhitaki's pharmacology is gallic acid (3,4,5-trihydroxybenzoic acid), released as the tannins are hydrolyzed in the gut. Gallic acid is a small, well-absorbed phenolic with several distinct activities relevant to human health.\n\nXanthine oxidase inhibition. Xanthine oxidase is the enzyme that converts purines into uric acid, and it is the same target hit by allopurinol and febuxostat. Bibhitaki extract and gallic acid inhibit this enzyme in vitro, which is the mechanistic basis for the uric-acid-lowering effect seen in human trials [1][2][7].\n\nPancreatic lipase inhibition. In obese diabetic mice, gallic acid from bibhitaki blocked the absorption of dietary fat by inhibiting pancreatic lipase — the same general mechanism as the prescription weight-loss drug orlistat, though milder [4]. This mechanism dovetails with the reductions in hyperlipidemia seen in the same study.\n\nInsulin and glucose handling. In isolated pancreatic beta cells and adipocytes, bibhitaki extract boosted insulin secretion in a calcium-dependent way and tripled insulin-stimulated glucose uptake in fat cells, while also slowing starch digestion and inhibiting protein glycation [3]. These four effects together cover most of the major levers in postprandial glucose control.\n\nAntioxidant and anti-inflammatory signaling. Bibhitaki extract activates the Nrf2/AMPK pathway and suppresses NF-kB-driven inflammation in macrophages, lowering TNF-alpha, IL-1 beta, and the LOX-1 receptor that takes oxidized LDL into the artery wall [6][7].\n\nPractical Use\n\nStandardized bibhitaki extracts have been studied at 500 to 2000 mg per day, divided into two doses, in human trials [1][2]. Traditional Ayurvedic dosing for the dried fruit powder ranges roughly from 1 to 3 g per day. Bibhitaki has a strongly astringent, drying taste — most people find it more tolerable as a capsule or as part of a Triphala blend than as plain powder.\n\nBecause bibhitaki lowers uric acid and modestly lowers blood glucose, anyone on allopurinol, febuxostat, or diabetes medication should monitor labs and coordinate with a clinician before adding it. People with chronic kidney disease should likewise involve their nephrologist; the most encouraging human data are in this population, but kidney patients are also the ones most sensitive to drug-herb interactions and dose mistakes.\n\nFor the broader Triphala context and the other two fruits, see our Triphala page, Haritaki page, and Amla page. For complementary uric-acid and metabolic strategies, see our Tart Cherry page and Quercetin page.","deepText":"Evidence Review\n\nHyperuricemia Pilot RCT (Usharani et al., 2016)\n\nThis 24-week, double-blind, placebo- and active-controlled pilot trial randomized 110 eligible subjects with hyperuricemia to one of five arms: T. chebula 500 mg twice daily, T. bellerica 250 mg twice daily, T. bellerica 500 mg twice daily, febuxostat 40 mg once daily, or placebo [1]. T. bellerica 500 mg twice daily lowered serum uric acid from a baseline of 8.07 plus or minus 0.87 mg/dL to 5.78 plus or minus 0.25 mg/dL by week 24, a roughly 28 percent reduction; febuxostat lowered it from 8.53 plus or minus 0.97 mg/dL to 4.28 plus or minus 0.67 mg/dL (about 50 percent reduction). Serum uric acid fell significantly from baseline as early as 4 weeks with T. bellerica 500 and 250 mg and febuxostat (p less than 0.001) and with T. chebula 500 mg (p less than 0.01), whereas it rose with placebo (p less than 0.05). The reduction with T. bellerica 500 mg was nearly twice that with T. chebula 500 mg or T. bellerica 250 mg at all time points, so the effect of T. bellerica appeared dose dependent. No serious adverse effects were reported, and all formulations were well tolerated. Strengths: double-blind design, placebo control, active comparator, clinically meaningful primary endpoint, 24-week duration. Limitations: pilot scale, a surrogate endpoint (serum uric acid) rather than gout flares, and the authors' call for further studies to confirm the potential.\n\nDose-Response RCT in Chronic Kidney Disease (Pingali et al., 2020)\n\nThe same group followed up with a 24-week, double-blind, three-arm dose-response trial in 59 stage 2 to 3 CKD patients with hyperuricemia [2]. Patients received febuxostat 40 mg once daily, T. bellerica extract 500 mg twice daily, or T. bellerica extract 1000 mg twice daily. By week 24, mean serum uric acid had fallen 63.7 percent in the febuxostat arm, 19.8 percent in the 500 mg bibhitaki arm, and 33.9 percent in the 1000 mg bibhitaki arm (p less than or equal to 0.0001 across groups). All three arms also showed significant reductions in serum creatinine starting at week 16 and increases in estimated glomerular filtration rate at weeks 20 and 24, with the 1000 mg bibhitaki dose described by the authors as \"as good as febuxostat\" on these kidney function markers. Markers of endothelial function and oxidative stress also improved in both bibhitaki arms. Strengths: dose-response design, active comparator, clinically relevant population, kidney function endpoints. Limitations: no placebo arm; modest sample size; single center; no hard renal outcomes such as need for dialysis.\n\nIn Vitro Insulin and Antidiabetic Mechanism (Kasabri, Flatt, Abdel-Wahab, 2010)\n\nPublished in the British Journal of Nutrition, this study tested aqueous T. bellirica extract on clonal pancreatic beta cells (BRIN-BD11), 3T3-L1 adipocytes, and isolated mouse abdominal muscle [3]. The extract stimulated basal insulin secretion concentration-dependently and potentiated glucose-stimulated insulin secretion (p less than 0.001), with the effect dependent on extracellular calcium and cell depolarization. In adipocytes, the extract enhanced insulin-stimulated glucose uptake by approximately 300 percent over insulin alone. The extract also reduced in vitro starch digestion by 10 to 50 percent and inhibited protein glycation. Strengths: multiple complementary assays mapping onto distinct anti-diabetic targets; results consistent with traditional use. Limitations: in vitro only; doses used in cell culture do not directly translate to oral human dosing because of bioavailability and metabolism of tannins.\n\nSpontaneously Obese Type 2 Diabetic Mouse Study (Makihara et al., 2012)\n\nResearchers fed TSOD mice — a strain that develops obesity, insulin resistance, and dyslipidemia spontaneously — a hot-water extract of T. bellirica fruit for an extended period and tracked body weight, fat accumulation, glucose tolerance, and lipid profile [4]. Treated mice showed less body weight gain, less visceral fat, improved glucose tolerance, and lower plasma triglycerides and cholesterol versus controls. In follow-up assays, gallic acid was identified as the active component responsible for inhibiting pancreatic lipase activity. The authors concluded that the metabolic benefits operate at least in part through reduced absorption of dietary fat. Strengths: physiologically relevant disease model rather than chemical induction; identifies a specific molecular mechanism. Limitations: animal model; effective doses in mice (typically 100 to 500 mg/kg) do not map cleanly to human dosing.\n\nHepatoprotection by Gallic Acid (Anand et al., 1997)\n\nThis bioassay-guided fractionation study isolated 3,4,5-trihydroxybenzoic acid — gallic acid — as the active hepatoprotective compound from T. belerica fruit [5]. In the carbon tetrachloride model of liver injury, gallic acid significantly reversed elevations in serum transaminases (AST, ALT) and bilirubin, normalized hexobarbitone-induced sleep time and zoxazolamine paralysis time (functional readouts of hepatic drug-metabolizing capacity), reduced lipid peroxidation in liver tissue, and restored glucose-6-phosphatase activity. The study established the mechanistic basis for traditional Ayurvedic use of bibhitaki as a liver remedy and identified the compound responsible. Strengths: bioassay-guided isolation, multiple complementary readouts of liver function and damage. Limitations: animal model with chemical induction; older study with smaller cohort sizes typical of the era.\n\nLDL Oxidation and Macrophage Inflammation (Tanaka et al., 2016) …","deepTruncated":true,"references":[{"id":"1","title":"A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia","authors":"Pingali Usharani, Chandrasekhar Nutalapati, Venkata Kishan Pokuri, Chiranjeevi Uday Kumar, Gangadhar Taduri","year":2016,"journal":"Clinical Pharmacology: Advances and Applications","pmid":"27382337","url":"https://pubmed.ncbi.nlm.nih.gov/27382337/"},{"id":"2","title":"A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia","authors":"Pingali Usharani, Chandrasekhar Nutalapati, Niranjan Koilagundla, Gangadhar Taduri","year":2020,"journal":"BMC Complementary Medicine and Therapies","pmid":"32933504","url":"https://pubmed.ncbi.nlm.nih.gov/32933504/"},{"id":"3","title":"Terminalia bellirica stimulates the secretion and action of insulin and inhibits starch digestion and protein glycation in vitro","authors":"Violet Kasabri, Peter R Flatt, Yasser H A Abdel-Wahab","year":2010,"journal":"British Journal of Nutrition","pmid":"19723351","url":"https://pubmed.ncbi.nlm.nih.gov/19723351/"},{"id":"4","title":"Preventive effect of Terminalia bellirica on obesity and metabolic disorders in spontaneously obese type 2 diabetic model mice","authors":"Hiroko Makihara, Tsutomu Shimada, Eriko Machida, Masatomi Oota, Rika Nagamine, Masahito Tsubata, Kaoru Kinoshita, Kunio Takahashi, Masaki Aburada","year":2012,"journal":"Journal of Natural Medicines","pmid":"22105160","url":"https://pubmed.ncbi.nlm.nih.gov/22105160/"},{"id":"5","title":"3,4,5-Trihydroxy benzoic acid (gallic acid), the hepatoprotective principle in the fruits of Terminalia belerica - bioassay guided activity","authors":"Anand KK, Singh B, Saxena AK, Chandan BK, Gupta VN, Bhardwaj V","year":1997,"journal":"Pharmacological Research","pmid":"9425622","url":"https://pubmed.ncbi.nlm.nih.gov/9425622/"},{"id":"6","title":"Terminalia bellirica Extract Inhibits Low-Density Lipoprotein Oxidation and Macrophage Inflammatory Response in Vitro","authors":"Tanaka M, Kishimoto Y, Saita E, Suzuki-Sugihara N, Kamiya T, Taguchi C, Iida K, Kondo K","year":2016,"journal":"Antioxidants (Basel)","pmid":"27314393","url":"https://pubmed.ncbi.nlm.nih.gov/27314393/"},{"id":"7","title":"Terminalia bellirica (Gaertn.) roxb. (Bahera) in health and disease: A systematic and comprehensive review","authors":"Gupta A, Kumar R, Bhattacharyya P, Bishayee A, Pandey AK","year":2020,"journal":"Phytomedicine","pmid":"32781393","url":"https://pubmed.ncbi.nlm.nih.gov/32781393/"}],"wordCount":1681,"source":{"path":"src/content/topics/bibhitaki/uric-acid-lipids-and-liver.md"},"citeAs":"“Does bibhitaki (Terminalia bellirica) lower uric acid?.” What's Healthy and Why. https://whatshealthyandwhy.com/bibhitaki/uric-acid-lipids-and-liver","notice":"General information backed by peer-reviewed research, not medical advice."}